Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?

Current Drug Safety

Volumn 4, Issue 1, 2009, Pages 84-93

  Odagaki, Yuji ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

5 HTT1A receptor; Atypical antipsychotics; Neuroleptic malignant syndrome; Partial agonist; Serotonin syndrome; Serotonin toxicity

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; DANTROLENE; DOPAMINE RECEPTOR STIMULATING AGENT; EMONAPRIDE; FLUPHENAZINE; HALOPERIDOL; IPSAPIRONE; LITHIUM SALT; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TANDOSPIRONE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE; ZOTEPINE; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST;

CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG INDUCED DISEASE; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERTHERMIA; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM; SIDE EFFECT; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG POTENTIATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS;

EID: 63249132909     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488609787354387     Document Type: Review

References (133)

1. Grohmann R, Engel RR, Geissler KH, Rüther E. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 2004; 37 (Suppl 1): S27-38.
2. Davis E, Bunk C, Specka M, Gastpar M. Psychotropic drug prescription in a psychiatric university hospital in Germany. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1109-16.
3. Rittmannsberger H, Meise U, Schauflinger K, Horvath E, Donat H, Hinterhuber H. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999; 17: 1-8.
4. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142: 1137-45.
5. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986; 73: 337-47.
6. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987; 22: 1004-20.
7. Caroff SN, Mann SC, Lazarus A, Sullivan K, MacFadden W. Neuroleptic malignant syndrome: diagnostic issues. Psychiatric Annals 1991; 21: 130-47.
8. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 27: 185-202.
9. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv 1998; 49: 1163-72.
10. Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf 1998; 19: 73-82.
11. Mann SC, Caroff SN, Lazarus A. Pathogenesis of neuroleptic malignant syndrome. Psychiatr Ann 1991; 21: 175-80.
12. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999; 156: 169-80.
13. Stübner S, Rustenbeck E, Grohmann R, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 2004; 37 (Suppl 1): S54-64.
14. Keck PE Jr, Pope HG Jr, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry 1989; 46: 914-8.
15. Caroff SN, Mann SC, Campbell EC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Annals 2000; 30: 314-21.
16. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-13.
17. Sporer KA. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf 1995; 13: 94-104.
18. Martin TG. Serotonin syndrome. Ann Emerg Med 1996; 28: 520-7.
19. Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin 1997; 13: 763-83.
20. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol 1998; 12: 482-91.
21. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999; 13: 100-9.
22. Keck PE Jr, Arnold LM. The serotonin syndrome. Psychiatr Ann 2000; 30: 333-43.
23. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000; 79: 201-9.
24. Radomski JW, Dursun SM, Reveley MA, Kutcher SP. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses 2000; 55: 218-24.
25. Ener RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin syndrome and other serotonergic disorders. Pain Med 2003; 4: 63-74.
26. Boyer EW, Shannon M. The serotonin syndrome. New Engl J Med 2005; 352: 1112-20.
27. Primeau F, Fontaine R, Chouinard G. Poorly controlled EPS: risk factors for NMS (letter). Can J Psychiatry 1987; 32: 328-9.
28. Levinson DF, Simpson GM. Neuroleptic-induced extrapyramidal symptoms with fever. Heterogeneity of the 'neuroleptic malignant syndrome'. Arch Gen Psychiatry 1986; 43: 839-48.
29. Weller M, Kornhuber J. Does clozapine cause neuroleptic malignant syndrome? (letter) J Clin Psychiatry 1993; 70-1.
30. Thornberg SA, Ereshefsky L. Neuroleptic malignant syndrome associated with clozapine monotherapy. Pharmacotherapy 1993; 13: 510-4.
31. Sachdev P, Kruk J, Kneebone M, Kissane D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1995; 15: 365-71.
32. Tsai G, Crisostome G, Rosenblatt ML, Stern TA. Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry 1995; 7: 91-5.
33. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998; 155: 1113-6.
34. Karagianis JL, Phillips LC, Hogan KP, LeDrew KK. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother 1999; 33: 623-30.
35. Farver DK. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2003; 2: 21-35.
36. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 464-70.
37. Gurrera RJ, Chang SS, Romero JA. A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry 1992; 53: 56-62.
38. Kozaric-Kovacic D, Folnegovic-Smalc V, Mimica N, Makarie G, Kocijan-Hercigonja. Incidence of neuroleptic malignant syndrome during a 10-year follow up at a psychiatric department. Neurol Croatica 1994; 43: 87-93.
39. Murty RG, Mistry SG, Chacko RC. Neuroleptic malignant syndrome with ziprasidone (letter). J Clin Psychopharmacol 2002; 22: 624-6.
40. Gray NS. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge. Hum Psychopharmcol Clin Exp 2004; 19: 205-7.
41. Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in adolescent. Clin Ther 2004; 26: 1105-8.
42. Borovicka MC, Bond LC, Gaughan KM. Ziprasidone- and lithium-induced neuroleptic malignant syndrome. Ann Pharmacother 2006; 40: 139-42.
43. Strawn JR, Keck PE Jr. Early bicarbonate loading and dantroline for ziprasidone/haloperidol-induced neuroleptic malignant syndrome (letter). J Clin Psychiatry 2006; 67: 677.
44. Ozen ME, Yumru M, Savas HA, Cansel N, Herken H. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. World J Biol Psychiatry 2007; 8: 42-4.
45. Nakagawa M, Matsumura T, Kato D, et al. Neuroleptic malignant syndrome induced by perospirone (letter). Int J Neuropsychopharmacol 2006; 9: 635-6.
46. Tanii H, Fujita K, Okazaki Y. Neuroleptic malignant syndrome related to a switch to perospirone and anticholinergic withdrawal (letter). Am J Psychiatry 2006; 163: 547-8.
47. Onrust SV, McClellan K. Perospirone. CNS Drugs 2001; 15: 329-37.
48. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-9.
49. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, Part 1. "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001; 62: 841-2.
50. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, Part 2. Illustrating their mechanism of action. J Clin Psychiatry 2001; 62: 923-4.
51. Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol 2004; 19: 351-3.
52. Spalding S, Alessi NE, Radwan K. Aripiprazole and atypical neuroleptic malignant syndrome (letter). J Am Acad Child Adolesc Psychiatry 2004; 43: 1457-8.
53. Duggal HS, Kithas J. Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine (letter). Am J Psychiatry 2005; 162: 397-8.
54. Ali S, Pearlman RL, Upadhyay A, Patel P. Neuroleptic malignant syndrome with aripiprazole and lithium: a case report (letter). J Clin Psychopharmacol 2006; 26: 434-6.
55. Hammerman S, Lam C, Caroff SN. Neuroleptic malignant syndrome and aripiprazole (letter). J Am Acad Child Adolesc Psychiatry 2006; 45: 639-41.
56. Kang S-G, Lee H-J, Lee M-S, Kim L, Park J-S. Atypical neuroleptic malignant syndrome associated with aripiprazole (letter). J Clin Psychopharmacol 2006; 26: 534.
57. Srephichit S, Sanchez R, Bourgeois JA. Neuroleptic malignant syndrome and aripiprazole in an antipsychotic-naïve patient (letter). J Clin Psychopharmacol 2006; 26: 94-5.
58. Brunelle J, Guigueno S, Gouin P, Tamion F, Thibaut F. Aripiprazole and neuroleptic malignant syndrome (letter). J Clin Psychopharmacol 2007; 27: 212-4.
59. Palakurtbi HB, Parvin MM, Kaplan S. Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient. Clin Neuropharmacol 2007; 30: 47-51.
60. Jordan S, Johnson JL, Regardie K, et al. Dopamin D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling. Prog Neuropsychopharmacol Biol Psychiat 2007; 31: 348-56.
61. Odagaki Y. Partial dopamine receptor agonists as newer atypical antipsychotics: intrinsic activity appropriate for treatment of schizophrenic patients. CNS Agents Med Chem 2007; 7: 156-65.
62. Strawn JR. Aripiprazole and the neuroleptic malignant syndrome (letter). Schizophr Res 2006; 85: 298-9.
63. Picard LS, Lindsay S, Strawn JR, Kaneria R, Patel NC, Keck PE Jr. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy 2008; 28: 530-5.
64. Price WA, Giannini AJ. A paradoxical response to chlorpromazine - a possible variant of the neuroleptic malignant syndrome. J Clin Pharmacol 1983; 23: 567-9.
65. Twemlow SW, Bair GO. Neuroleptic malignant syndrome. Association with thioridazine hydrochloride in a manic depressive patient. J Kansas Med Soc 1983; 84: 523-33.
66. Misiaszek JJ, Potter RL. Atypical neuroleptic malignant syndrome responsive to conservative management. Psychosomatics 1985; 26: 62-6.
67. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 1986; 143: 1587-90.
68. Conlon P. The spectrum concept of neuroleptic toxicity (letter). Am J Psychiatry 1986; 143: 811.
69. Sullivan CF. A possible variant of the neuroleptic malignant syndrome. Br J Psychiatry 1987; 151: 689-90.
70. Velamoor VR, Fernando MLD, Williamson P. Incipient neuroleptic malignant syndrome? Br J Psychiatry 1990; 156: 581-4.
71. Nopoulos P, Flaum M, Miller DD. Atypical neuroleptic malignant syndrome (NMS) with an atypical neuroleptic. Clozapine-induced NMS without rigidity. Ann Clin Psychiatry 1990; 2: 251-3.
72. Amore M, Zazzeri N, Berardi D. Atypical neuroleptic malignant syndrome associated with clozapine treatment. Neuropsychobiology 1997; 35: 197-9.
73. Choi-Kain LW, Pope HG. "Atypical" neuroleptic malignant syndrome and the spectrum of malignant cerebrotoxic syndromes. Harv Rev Psychiatry 2007; 15: 181-6.
74. Dalkin T, Lee AS. Carbamazepine and forme fruste neuroleptic malignant syndrome. Br J Psychiatry 1990; 157: 437-8.
75. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV TR). Washington, DC: American Psychiatric Association; 2000: 795-8.
76. Pope HG Jr, Keck PE Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986; 143: 1227-33.
77. Buckley PF, Hasan S. Atypical neuroleptic malignant syndrome and atypical antipsychotics (letter). Am J Psychiatry 1998; 155: 1626.
78. Fogel BS, Goldberg RJ. Neuroleptic malignant syndrome (letter). New Engl J Med 1985; 313; 1292.
79. Adityanjee, Singh S, Singh G, Ong S. Spectrum concept of neuroleptic malignant syndrome. Br J Psychiatry 1988; 153: 107-11.
80. Walker WD. Spectrum concept of neuroleptic malignant syndrome (letter). Br J Psychiatry 1988; 153: 574.
81. Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 1992; 31: 1161-4.
82. Nierenberg D, Disch M, Manheimer E, et al. Facilitating prompt diagnosis and treatment of the neuroleptic malignant syndrome. Clin Pharmacol Ther 1991; 50: 580-6.
83. Fink M, Taylor MA. The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 2001; 251 (Suppl 1); 8-13.
84. Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry 1989; 146: 324-8.
85. Rusyniak DE, Sprague JE. Hyperthermic syndromes induced by toxins. Clin Lab Med 2006; 26: 165-84.
86. 1A receptors. Neuropharmacology 1996; 35: 119-21.
87. 1A receptors: a 35SGTP..S binding study. Eur J Pharmacol 1998; 355: 245-56.
88. 1A receptor. Eur J Pharmacol 2002, 441: 137-40.
89. 1A receptors in human post-mortem brain. Eur J Pharmacol 1999; 386: 313-5.
90. Newman-Tancredi A, Assié M-B, Leduc N, Ormière A-M, Danty N, Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 2005; 8: 341-56.
91. 35S]GTPγS binding in rat hippocampal membranes. Clin Exp Pharmacol Physiol 2007; 34: 462-6.
92. 35S]GTPγS binding in rat hippocampal membranes. J Pharmacol Sci 2005; 98: 66-76.
93. 35S]GTPγS binding. J Psychopharmacol 2005; 19: 235-41.
94. Pecknold JC. A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Drug Saf 1997; 16: 118-32.
95. Yamawaki S. The use and development of anxiolytics in Japan. Eur Neuropsychopharmacol 1999; 9 (Suppl 6): S413-9.
96. 1A receptors. J Pharmacol Exp Ther 2000; 295: 853-61.
97. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 2001; 15: 37-46.
98. Goldberg RJ, Huk M. Serotonin syndrome from trazodone and buspirone (letter). Psychosomatics 1992; 33: 235-6.
99. Baets M, Malcolm D. Serotonin syndrome from fluvoxamine and buspirone (letter). Can J Psychiatry 1995; 40: 428-9.
100. Nijhawan PK, Katz G, Winter S. Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission. Crit Care Med 1996; 24: 1086-9.
101. Spigset O, Adielsson G. Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction. Int Clin Psychopharmacol 1997; 12: 61-3.
102. Bonin B, Vandel P, Vandel S, Sechter D, Bizouard P. Serotonin syndrome after sertraline, buspirone and loxapine? (letter) Therapie 1999; 54: 269-71.
103. Manos GH. Possible serotonin syndrome associated with buspirone added to fluoxetine. Ann Pharmacother 2000; 34: 871-4.
104. Lantz MS. Serotonin syndrome. A common but often unrecognized psychiatric condition. Geriatrics 2001; 56: 52-3.
105. Dannawi M. Possible serotonin syndrome after combination of buspirone and St John's Wort (letter). J Pshychopharmacol 2002; 16: 401.
106. Höjer J, Personne M, Skagius A-S, Hansson O. Serotoninergt syndrom - flera allvarliga fall med denna ofta förbisedda diagnos (in Swedish). Tidsskr Nor Laegeforen 2002; 17: 1660-3.
107. Jägestedt M, von Bahr C. Kombination av serotonerga läkemedel gav kraftiga biverkningar (in Swedish). Lakartidningen 2004; 101: 1618-9.
108. Bogdanovic Z, Nalamatl JR, Kilcullen JK, Dhupeer S. Antidepressant-induced adverse reactions in a patient with hemorrhage stroke. Ann Pharmacother 2005; 39: 1755-7.
109. Tamura N, Nakazato Y, Yamamoto T, Iwasaki S, Shimazu K. Serotonin syndrome caused by tandospirone alone (in Japanese). Rinsho Shinkeigaku 2002; 42: 892-4.
110. Kaneda Y, Ohmori T, Okabe H. Possible mild serotonin syndrome related to co-prescription of tandospirone and trazodone (letter). Gen Hosp Psychiatry 2001; 23: 97-101.
111. Insel TR, Roy BF, Cohen RM, Murphy DL. Possible development of the serotonin syndrome in man. Am J Psychiatry 1982; 139: 954-5.
112. Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans. Implications for diagnosis and treatment. Clin Neuropharmacol 2005; 28: 205-14.
113. Jacobs BL. An animal behavior model for studying central serotonergic synapses. Life Sci 1976; 19: 777-86.
114. Nishijima K, Yoshino T, Ishiguro T. Risperidone counteracts lethality in animal model of the serotonin syndrome. Psychopharmacology (Berl) 2000; 150: 9-14.
115. Nishijima K, Yoshino T, Yui K, Katoh S. Potent serotonin (5-HT)2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res 2001; 890: 23-31.
116. 2 receptors (letter). Br J Psychiatry 2002; 88: 603.
117. Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 2006; 59: 1046-51.
118. Hegerl U, Bottlender R, Gallinat J, Kuss H-J, Ackenheil M, Möller H-J. The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci 1998; 248: 96-103.
119. Reeves RR, Mack JE, Beddingfield JJ. Neurotoxic syndrome associated with risperidone and fluvoxamine. Ann Pharmacother 2002; 36: 440-3.
120. Birnes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. CMAJ 2003; 168: 1439-42.
121. Cates ME. Ziprasidone - not an option for serotonin syndrome (letter). CMAJ 2003; 169: 1147-8.
122. Hamilton S, Malone K. Serotonin syndrome during treatment with paroxetine and risperidone (letter). J Clin Psychopharmacol 2000; 20: 103-5.
123. Karki SD, Masood G-R. Combination risperidone and SSRI-induced serotonin syndrome. Ann Pharmacother 2003; 37: 388-91.
124. Kohen I, Gordon ML, Manu P. Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports. CNS Spectr 2007; 12: 596-8.
125. Duggal HS, Fetchko J. Serotonin syndrome and atypical antipsychotics (letter). Am J Psychiatry 2002; 159: 672-3.
126. Haslett CD, Kumar S. Can olanzapine be implicated in causing serotonin syndrome? Psychiatry Clin Neurosci 2002; 56: 533-5.
127. Chopra P, Ng C, Schweizer I. Serotonin syndrome associated with fluoxetine and olanzapine. World J Biol Psychiatry 2004; 5: 114-5.
128. Verre M, Bossio F, Mammone A, et al. Serotonin syndrome caused by olanzapine. Minerva Anesth 2008; 74: 41-5.
129. Marlowe K, Schirgel D. Quetiapine and citalopram: aetiological significance in serotonin syndrome. N J Med J 2006; 119 (No 1237).
130. Kinzie E, Meltzer-Brody S. Possible serotonin syndrome with citalopram following cross-titration of clozapine to ziprasidone (letter). Gen Hosp Psychiatry 2005; 27: 223-4.
131. Umeda S, Hirano J, Shigemura J, Nibuya M, Nomura S. Serotonin syndrome induced by a minimum dose of paroxetine in a patient with moderate renal failure via an enhanced 5-hydroxytryptamine 1A receptor neurotransmission (in Japanese). Seishinka Chiryogaku 2008; 23: 239-43.
132. Isbister GK. Comment: combination risperidone and SSRI-induced serotonin syndrome (letter). Ann Pharmacother 2003; 37: 1531-2.
133. Isbister GK, Downes F, Whyte IM. Olanzapine and serotonin toxicity (letter). Psychiatry Clin Neurosci 2003; 57: 241-2.